Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet, Alexander Bello, Teresa Cabral, Jim E. Strong, Frank Plummer, Cindy R. Corbett, Judie B. Alimonti,

and Gary P. Kobinger

Sci Transl MedVolume 4(138):138ra81-138ra81

June 13, 2012

Published by AAAS

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs. (A) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow).

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS

Fig. 2 Clinical overview.

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS

Fig. 3 EBOV-GP–specific antibody response.

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS

Fig. 4 Cellular immune response in surviving animals 21 days after challenge.

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS

Fig. 5 Identification of IL-2 and IFN-γ–producing cells upon in vitro stimulation by EBOV-GP peptide pools using flow cytometry.

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS

Fig. 6 EBOV-GP sequences isolated from nonsurvivors.

Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81

Published by AAAS